<?xml version='1.0' encoding='utf-8'?>
<document id="21371863"><sentence text="Impact of concomitant use of proton-pump inhibitors and thienopyridine derivatives on the antiplatelet effects."><entity charOffset="56-70" id="DDI-PubMed.21371863.s1.e0" text="thienopyridine" /></sentence><sentence text="Although there has been an intense debate whether concomitant use of proton-pump inhibitors (PPIs) attenuates the antiplatelet effects of thienopyridine derivatives, the drug-drug interaction remains unclear in Japanese patients with coronary artery disease"><entity charOffset="138-152" id="DDI-PubMed.21371863.s2.e0" text="thienopyridine" /></sentence><sentence text="" /><sentence text="Platelet function test was performed in 461 patients who were scheduled for or had undergone stent implantation, treated with 100mg/day of aspirin and a thienopyridine (200mg/day of ticlopidine or 75 mg/day of clopidogrel) for at least 14 days"><entity charOffset="139-146" id="DDI-PubMed.21371863.s4.e0" text="aspirin" /><entity charOffset="153-167" id="DDI-PubMed.21371863.s4.e1" text="thienopyridine" /><entity charOffset="182-193" id="DDI-PubMed.21371863.s4.e2" text="ticlopidine" /><entity charOffset="210-221" id="DDI-PubMed.21371863.s4.e3" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.21371863.s4.e0" e2="DDI-PubMed.21371863.s4.e0" /><pair ddi="false" e1="DDI-PubMed.21371863.s4.e0" e2="DDI-PubMed.21371863.s4.e1" /><pair ddi="false" e1="DDI-PubMed.21371863.s4.e0" e2="DDI-PubMed.21371863.s4.e2" /><pair ddi="false" e1="DDI-PubMed.21371863.s4.e0" e2="DDI-PubMed.21371863.s4.e3" /><pair ddi="false" e1="DDI-PubMed.21371863.s4.e1" e2="DDI-PubMed.21371863.s4.e1" /><pair ddi="false" e1="DDI-PubMed.21371863.s4.e1" e2="DDI-PubMed.21371863.s4.e2" /><pair ddi="false" e1="DDI-PubMed.21371863.s4.e1" e2="DDI-PubMed.21371863.s4.e3" /><pair ddi="false" e1="DDI-PubMed.21371863.s4.e2" e2="DDI-PubMed.21371863.s4.e2" /><pair ddi="false" e1="DDI-PubMed.21371863.s4.e2" e2="DDI-PubMed.21371863.s4.e3" /></sentence><sentence text=" Adenosine diphosphate-induced platelet aggregation was evaluated with screen filtration pressure method, and the upper quartile of high platelet reactivity was defined as high on-treatment platelet reactivity (HPR)"><entity charOffset="1-22" id="DDI-PubMed.21371863.s5.e0" text="Adenosine diphosphate" /></sentence><sentence text=" PPI use was at physician's discretion" /><sentence text=" Patients taking a thienopyridine plus a PPI (n=166) were older and had a higher incidence of acute coronary syndromes on admission compared with patients taking a thienopyridine without a PPI (n=295)"><entity charOffset="19-33" id="DDI-PubMed.21371863.s7.e0" text="thienopyridine" /><entity charOffset="164-178" id="DDI-PubMed.21371863.s7.e1" text="thienopyridine" /><pair ddi="false" e1="DDI-PubMed.21371863.s7.e0" e2="DDI-PubMed.21371863.s7.e0" /><pair ddi="false" e1="DDI-PubMed.21371863.s7.e0" e2="DDI-PubMed.21371863.s7.e1" /></sentence><sentence text=" The rate of HPR was higher in patients taking a thienopyridine plus a PPI than in patients taking a thienopyridine without a PPI (31% vs 21%, p=0"><entity charOffset="49-63" id="DDI-PubMed.21371863.s8.e0" text="thienopyridine" /><entity charOffset="101-115" id="DDI-PubMed.21371863.s8.e1" text="thienopyridine" /><pair ddi="false" e1="DDI-PubMed.21371863.s8.e0" e2="DDI-PubMed.21371863.s8.e0" /><pair ddi="false" e1="DDI-PubMed.21371863.s8.e0" e2="DDI-PubMed.21371863.s8.e1" /></sentence><sentence text="01)" /><sentence text=" On multivariate logistic regression analysis, independent predictors of HPR were concomitant PPI use [odds ratio (OR): 1" /><sentence text="66, 95% confidence interval (CI): 1" /><sentence text="03-2" /><sentence text="68], diabetes mellitus (OR: 1" /><sentence text="76, CI: 1" /><sentence text="11-2" /><sentence text="81), and calcium channel blockers use (OR: 1"><entity charOffset="9-16" id="DDI-PubMed.21371863.s16.e0" text="calcium" /></sentence><sentence text="93, CI: 1" /><sentence text="18-3" /><sentence text="18)" /><sentence text=" However, there was no significant difference in the rate of extremely high platelet reactivity [58 patients (12" /><sentence text="5%) with PATI&lt;4" /><sentence text="0 Î¼M] between patients treated with a thienopyridine plus a PPI and those without a PPI (14% vs 11%, NS)"><entity charOffset="38-52" id="DDI-PubMed.21371863.s22.e0" text="thienopyridine" /></sentence><sentence text="" /><sentence text="HPR was frequently observed in Japanese patients treated with thienopyridines plus PPIs compared to those without PPIs"><entity charOffset="62-77" id="DDI-PubMed.21371863.s24.e0" text="thienopyridines" /></sentence><sentence text=" Further prospective studies are needed to estimate the risk of adverse cardiovascular events associated with concomitant use of PPIs and thienopyridines"><entity charOffset="138-153" id="DDI-PubMed.21371863.s25.e0" text="thienopyridines" /></sentence><sentence text="" /></document>